{"id":"W4402389020","doi":"10.1200/jco.24.00767","title":"Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Cabozantinib; Sunitinib; Medicine; Crizotinib; Clinical endpoint; Internal medicine; Hazard ratio; Papillary renal cell carcinomas; Oncology; Renal cell carcinoma; Axitinib; Pazopanib; Clinical trial; Urology; Confidence interval; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006596887,0.002233154,0.003709873,0.0006614847,0.0003933072,0.001417229,0.001008405,0.001453135,0.002972546],"category_scores_gemma":[0.003370269,0.0006658867,0.005842331,0.0004604241,0.001309384,0.001411468,0.0006078766,0.003242604,0.0005813162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001377658,"about_ca_system_score_gemma":0.002025437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007200663,"about_ca_topic_score_gemma":0.00203568,"domain_scores_codex":[0.9972576,0.001731801,0.0001467783,0.0004014567,0.0001899565,0.0002722995],"domain_scores_gemma":[0.9975907,0.000625932,0.0005449301,0.0002544542,0.0001981451,0.0007859733],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9620928,0.006293203,0.003253746,0.0004879623,0.003806137,0.00005253579,0.00007092626,0.002052299,0.005211174,0.0001743728,0.001268191,0.01523673],"study_design_scores_gemma":[0.672164,0.3021682,0.01436644,0.00004030029,0.004301683,0.0001371134,0.00005847942,0.003194987,0.001879036,0.0004131797,0.001222734,0.00005396931],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924619,0.001859399,0.000989772,0.0002814412,0.0001583501,0.001488837,0.001532267,0.00009177598,0.001136349],"genre_scores_gemma":[0.9900356,0.0006912632,0.001885241,0.0004927475,0.0001730998,0.00165258,0.00381835,0.00003771587,0.001213389],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006596887,"threshold_uncertainty_score":0.03488815,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1291674654152644,"score_gpt":0.437636004799056,"score_spread":0.3084685393837916,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}